Research documentation · FAQ
PT-141: Frequently Asked Questions
Direct answers about PT-141 (bremelanotide) from the published literature and the approved label — definitional, mechanistic, dosing, and efficacy.
Does PT-141 work?
In two Phase 3 RCTs (RECONNECT) in premenopausal women with HSDD, bremelanotide 1.75 mg subcutaneous as-needed met both coprimary endpoints with statistically significant but clinically modest improvements in desire and desire-related distress [3]. Benefit outside that approved population is not established. Independent re-analyses argue the effect, while real, is small [3].
What were the results of the PT-141 clinical trials?
The RECONNECT trials (n=1267) showed integrated FSFI-desire +0.35 (P<.001) and FSDS-DAO item 13 -0.33 (P<.001) versus placebo over 24 weeks [3]. A 52-week open-label extension (684 women) sustained the effect with no new safety signals [4]. Both coprimary endpoints were met in both trials [3].
What are the benefits of PT-141?
In the approved indication, the documented benefit is a modest increase in sexual desire and a reduction in distress about low desire in premenopausal women with HSDD [3][4]. The magnitude has been debated as small in critical re-analyses [3]. No benefit is established in men, after menopause, or for sexual performance.
How big is the effect of bremelanotide on sexual desire?
Integrated trial effects were +0.35 on the FSFI desire domain and -0.33 on FSDS-DAO item 13 versus placebo [3]. Independent re-analyses (Spielmans 2021, 2024) argue these effects, while statistically significant, are small and of debatable clinical meaningfulness [3]. Both the significance and the modest size are real.
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin receptors (MC3R/MC4R) [1][6]. As bremelanotide it is FDA-approved (NDA 210557, 2019) for HSDD in premenopausal women [6].
What is PT-141 peptide?
It is a seven-amino-acid cyclic peptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, related to melanotan II [6]. It acts on melanocortin receptors in the brain rather than on blood vessels, which distinguishes it from the PDE-5 inhibitor class [1].
What does the PT-141 peptide do?
It stimulates MC4R (and MC3R) in hypothalamic and limbic circuits, engaging dopaminergic pathways linked to sexual motivation [1]. In the approved use it raises sexual desire in premenopausal women with HSDD [3]. A 2022 fMRI study showed it altering brain processing of sexual cues [13].
What is PT-141 used for?
As bremelanotide it is approved only for acquired, generalized HSDD in premenopausal women [6]. Uses in men, for erectile dysfunction, or in postmenopausal women are off-label and supported only by early-phase or investigational evidence [1][6].
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the development/research code; bremelanotide is the international nonproprietary name (INN) for the same molecule [6]. It was approved under NDA 210557 in June 2019 [6]. The research-chemical label and the approved drug name refer to the same compound, but not the same regulated product.
What is bremelanotide?
Bremelanotide is the approved melanocortin receptor agonist — the INN for PT-141 — administered as a 1.75 mg subcutaneous injection as needed for HSDD in premenopausal women [5][6]. It received its first regulatory approval in the United States in June 2019 [6].
How does PT-141 work?
It activates central melanocortin receptors, chiefly MC4R, in hypothalamic circuits such as the medial preoptic area, engaging dopamine signaling tied to sexual desire [1]. Unlike PDE-5 inhibitors it acts on the brain, not on vascular blood flow [1]. A 2022 fMRI study confirmed central effects in women with HSDD [13].
What receptors does PT-141 act on?
Primarily the melanocortin 4 receptor (MC4R), with secondary activity at MC3R [6]. Peripheral MC1R activation explains the hyperpigmentation seen with repeated frequent dosing [5]. MC4R's presence in appetite circuits also accounts for the caloric-intake effects in high-frequency dosing [4][6].
Does PT-141 work through the brain or through blood flow?
Through the brain. It is a central melanocortin agonist acting on neural circuits of sexual motivation, mechanistically distinct from PDE-5 inhibitors that act peripherally on vascular smooth muscle [1]. A 2022 fMRI study showed measurable changes in central brain processing of sexual stimuli [13].
What is a melanocortin receptor agonist?
A compound that activates the melanocortin receptor family (MC1R-MC5R) [1]. PT-141 targets the central MC3R/MC4R subtypes that modulate sexual desire and appetite [6]. It is a synthetic analogue of the body's own alpha-MSH, the natural ligand for these receptors [1].
Does PT-141 increase testosterone?
No. PT-141 does not act via the HPG axis and does not directly raise testosterone [5]. It works on central melanocortin receptors — a different system entirely — which is a common point of confusion for a compound discussed in a sexual-function context [5].
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors (such as sildenafil) act peripherally on penile vascular smooth muscle to improve blood flow; PT-141 acts centrally on brain melanocortin receptors governing sexual motivation [1]. They address different mechanisms — vascular versus neural — and PT-141 is approved for desire in women, not erectile blood flow.
What is the PT-141 dosage?
In the approved label, bremelanotide is 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and no more than eight per month [5]. Reported as a label finding, not a protocol for any reader.
How much PT-141 should I take?
This site does not recommend a dose. The studied/approved figure is 1.75 mg subcutaneous as-needed in premenopausal women with HSDD [5]; Phase 2 explored 0.75, 1.25, and 1.75 mg [8]. Material sold as research chemical is for laboratory use only [5].
How much PT-141 to inject?
The approved subcutaneous dose studied in the RECONNECT program was 1.75 mg as needed [3][5]. This is reported as a trial/label finding, not as dosing guidance. The approved product is a ready-to-use subcutaneous autoinjector at that fixed dose [5].
How do you reconstitute PT-141?
The approved bremelanotide product is supplied as a ready-to-use subcutaneous autoinjector, not a powder requiring reconstitution [5]. The approved route in the trials and the label is subcutaneous [3][5]. Laboratory research material is a separate, unregulated product and is not the approved finished drug.
How do you take PT-141?
In the approved indication it is given by subcutaneous injection as needed before anticipated sexual activity, at least 45 minutes prior [5]. Early intranasal formulations were discontinued for pharmacokinetic variability [5]. This describes the labeled route, not a recommendation to administer it.
How often can you take PT-141?
The label limits dosing to no more than one 1.75 mg dose per 24 hours and no more than eight doses per month [5]. This frequency cap is reported as a label finding; the cap is also relevant to the hyperpigmentation seen with frequent repeated dosing [5].